Developmental Disability Animal Model Based on Neonatal Lipopolysaccharide with Altered 5-HT Function.
- Author:
Jae Goo KIM
1
;
Min Soo KIM
;
Seoul LEE
;
Gun Tae KIM
;
Jong Doo LEE
;
Dong Goo KIM
Author Information
1. Department of Pharmacology, Brain Korea 21 Project for Medical Sciences, Brain Research Institute, Yonsei University College of Medicine, Seoul 120-752, Korea.
- Publication Type:Original Article
- Keywords:
Developmental disability;
Lipopolysaccharide;
5-HT1A receptor;
Animal model
- MeSH:
Animals*;
Developmental Disabilities*;
Inflammation;
Models, Animal*;
Neurologic Manifestations;
Rats, Sprague-Dawley;
Receptor, Serotonin, 5-HT1A;
Serotonin*;
Tilt-Table Test
- From:The Korean Journal of Physiology and Pharmacology
2007;11(3):113-119
- CountryRepublic of Korea
- Language:English
-
Abstract:
Developmental disability shows life-long behavioral abnormality with no significant physical malformation. This study was undertaken to develop an animal model for developmental disability by using two-factor approach. Lipopolysaccharide (LPS), a bacterial toxin, and NAN-190, a 5-HT1A receptor antagonist, were administered to Sprague-Dawley rats on postnatal day (PND) 5 to induce inflammation and an altered 5-HT system, respectively. Long-term alteration of behavior occurred in the drug-treated groups. The LPS-treated group showed impaired motor coordination in the Rota-rod test. The LPS- treated or both LPS and NAN-190-treated groups showed impaired fore-paw muscle power in the wire maneuver test. These groups also showed decreased white matter volume and increased serotonergic fibers. The LPS and NAN-190-treated group also exhibited neurologic deficit in the placing reaction test and impaired equilibrium function in the tilt table test. The results showed that a variety of altered behaviors can be generated by two factor model, and suggested that combination of important etiologic factors and possible underlying defects is a promising strategy of establishing an animal model for developmental disabilities.